Jasper Therapeutics(US:JSPR)2025-11-10 13:05Financial Performance - Jasper Therapeutics reported a net loss of $18.7 million for the third quarter of fiscal 2025, translating to a net loss per share of $1.13[7] - Total operating expenses for the third quarter were $19.2 million, compared to $19.9 million in the same quarter of the previous year[11] - The accumulated deficit increased to $307.6 million as of September 30, 2025, compared to $240.9 million at the end of 2024[13] Expenses - Research and development expenses for the quarter were $14.4 million, while general and administrative expenses totaled $4.8 million[7] - The total liabilities as of September 30, 2025, were $45.9 million, with current liabilities at $21.0 million[13] Cash Position - As of September 30, 2025, cash and cash equivalents amounted to $50.9 million, following a successful $30 million underwritten offering of common stock and warrants[7] Clinical Studies - The company is investigating anomalous efficacy results from the BEACON study and plans to report final conclusions in the fourth quarter of 2025[4] - Initial data from the ETESIAN study in allergic asthma is expected to be reported in the fourth quarter of 2025, with additional data from the BEACON study anticipated in the first half of Q1 2026[2] - Jasper continues to enroll additional patients in the BEACON study and expects to complete dose selection for the planned Phase 2b CSU study by mid-2026[7] Product Potential - The company believes briquilimab has the potential to be a highly differentiated therapy for mast cell diseases based on preliminary results[2]